US Medical Affairs
Enter Product Gallery
For US Health Care Professionals Only
Back to Lobby
Site Map
Submit Medical Inquiry
Report Adverse Event
Contact Us
Corporate Responsibility
| Share
COVID-19 Response
Novartis’ response to COVID-19
Novartis is responding to COVID-19 with the safety of our associates and patients we serve as our main concern. We continue to contribute to global research efforts, support local communities and ensure stable supply and price of essential medicines. This US information center provides updates, guidance, and other resources
Visit Information Center
Xiidra® (lifitegrast ophthalmic solution) 5% Virtual Gallery
Novartis Main Lobby
Novartis Ophthalmics Product Gallery
BEOVU® (brolucizumab-dbll) Virtual Gallery
US Contacts
US Novartis
https://www.novartis.us
https://medinfo.novartispharmaceuticals.com
US Medical
https://medinfo.novartispharmaceuticals.com/EMedContactUs
https://ngcs.novartis.com/
US Novartis Grant Central Station (NGCS)
https://www.report.novartis.com
https://www.novartis.us/news/us-media-contacts
US Media Contacts
Use of website is governed by the Terms of Use and Privacy Policy. 5/22 187922 © 2022 Novartis Pharmaceuticals Corporation. All rights reserved.
Use of website is governed by the Terms of Use and Privacy Policy. 10/21 160595 © 2021 Novartis Pharmaceuticals Corporation. All rights reserved.
Use of website is governed by the Terms of Use and Privacy Policy. 10/21 163510 © 2021 Novartis Pharmaceuticals Corporation. All rights reserved.
| | Share
Use of website is governed by the Terms of Use and Privacy Policy. 10/21 160595 © 2022 Novartis Pharmaceuticals Corporation. All rights reserved.
Use of website is governed by the Terms of Use and Privacy Policy. 2/22 187922 © 2022 Novartis Pharmaceuticals Corporation. All rights reserved.
Full Prescribing Information
Click here for for BEOVU® (brolucizumab-dbll) injection
Click here for for Xiidra® (lifitegrast ophthalmic solution) 5%
XIIDRA, the XIIDRA logo and ii, are registered trademarks of Novartis AG.
Downloads
Xiidra Artificial Tears Flashcard
Xiidra Efficacy Leave Behind
Xiidra Technician Flashcard
Xiidra Prior Authorization Checklist
Interactive
Interactive Panels
View Tech Talks
Chapter 1: Identifying the Dry Eye Patient
Chapter 2: Speaking with Patients About DED
Chapter 3: Xiidra 101
Chapter 4: Xiidra Access Resources
Use of website is governed by the Terms of Use and Privacy Policy. 3/22 182397 © 2022 Novartis Pharmaceuticals Corporation. All rights reserved.
XIIDRA, the XIIDRA logo and ii are registered trademarks of Novartis AG.
VIEW INFORMATION AND RESOURCES
SEE THE LATEST DATA
LEARN HOW TO JOIN OUR PEER PROGRAMS
Reference: 1. Beovu [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2022.
Patient monitoring and counseling*
BEOVU is contraindicated in :
1
Guidance :
Safety remains at the heart of what we do. To support education and monitoring for patients with wet AMD, please see the following counseling guidance as well as a resource guide below.
Patients with ocular or periocular infections Patients with active intraocular inflammation Patients with known hypersensitivity to brolucizumab or any of the excipients in BEOVU
Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation
Advise patients there is a risk of developing endophthalmitis, retinal detachment, retinal vasculitis, and/or retinal vascular occlusion in the days following BEOVU administration Reports of retinol vasculitis and/or retinal vascular occlusion typically occurred in the presence of intraocular inflammation. These immune mediated adverse events may occur following the first intravitreal injection. Discontinue treatment with BEOVU in patients who develop these events. Patients treated with BEOVU who experience intraocular inflammation may be at risk of developing retinal vasculitis and/or retinal vascular occlusion and should be closely monitored. Patients should be monitored for increased intraocular pressure immediately following the intravitreal injection. Monitoring may include checking for perfusion of the optic nerve head or tonometry
Patients should be instructed to seek immediate care from their ophthalmologist if they experience any of the following symptoms or any change in vision :
Increased light sensitivity Floaters Pain in their eye Decrease in vision Redness on the white part of the eye
*This is a subset of information from the Prescribing Information. As always, please review the full Prescribing Information
We’ve developed a guide to help your patients monitor their vision at home and know what to do if they experience changes in vision:
Please see the Important Safety Information for BEOVU.
DOWNLOAD THE PATIENT VISION MONITORING GUIDE
DOWNLOAD THE FULL PRESCRIBING INFORMATION
Use of website is governed by the Terms of Use and Privacy Policy. 4/22 196934 © 2022 Novartis Pharmaceuticals Corporation. All rights reserved.
Use of website is governed by the Terms of Use and Privacy Policy. 3/22 XXXXXX © 2022 Novartis Pharmaceuticals Corporation. All rights reserved.
BEOVU is a registered trademark of Novartis AG.
Important Safety Information
BEOVUhcp.com
HELPFUL RESOURCES
Below you can watch BEOVU videos and download helpful resources for you and your patients
Core Story
Vision-Monitoring Guide
